← Back to Clinical Trials
Recruiting NCT06381271
Transcatheter Aortic Valve Replacement for Pure Severe Aortic Valve Regurgitation
Trial Parameters
Condition Aortic Valve Regurgitation
Sponsor Xijing Hospital
Study Type OBSERVATIONAL
Phase N/A
Enrollment 500
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2018-10-30
Completion 2034-10
Interventions
Transcatheter aortic valve replacement
Brief Summary
The purpose of this multicenter, prospective and observational registry is to evaluate the safety and efficacy of TAVR for treatment of pure severe aortic valve regurgitation. Baseline characteristics, procedural and clinical data will be collected
Eligibility Criteria
Inclusion Criteria: * 1\. Patients diagnosed with severe aortic valve regurgitation undergo evaluation by the Heart team and are eligible for TAVR therapy. * 2\. Patients who understand the purpose of this study, agree to participate in the trial and sign the informed consent form Exclusion Criteria: * 1\. Patients who cannot provide informed consent * 2\. Patients who are treated with TAVR for aortic stenosis * 3\. Patients who are participating in other clinical trials